Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05858632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Spatial Features of Guselkumab Cutaneous Response

Name: Immune Spatial Features of Guselkumab Cutaneous Response — clinical trial record (NCT05858632)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorUniversity of California, San Francisco

Started2023-07-01

View on ClinicalTrials.gov ↗

Amendment history

2026-06-01

Study Status v2

Primary completion date2026-06-30→2028-06-30

Completion date2026-06-30→2028-06-30

2023-08-25

Study Status v1

Re-verified, no change to tracked fields

2023-05-04

Original filing

University of California, San Francisco

637 trials monitored

See 53 trials at risk

Psoriasis

418 trials monitored

See 17 trials at risk

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Trial Details

NCT Number	NCT05858632
Lead Sponsor	University of California, San Francisco Collaborators: Janssen Scientific Affairs, LLC
Conditions	Psoriasis of Scalp
Enrollment	10 participants
Start Date	2023-07-01
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-04